Parental history of Alzheimer disease associated with lower plasma apolipoprotein e levels

Neurology

Volumn 73, Issue 9, 2009, Pages 681-687

  Van Vliet, P ^a,b   Westendorp, R G J ^b   Eikelenboom, P ^d   Comijs, H C ^d   Frolich M ^b   Bakker, E ^c   Van Der Flier, W ^c   Van Exel, E ^d  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Department of Clinical Chemistry ^*  (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E;

ADULT; ALLELE; ALZHEIMER DISEASE; ARTICLE; BLOOD ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENOTYPE; HETEROZYGOTE; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGENY; RISK;

ADULT; AGED; AGED, 80 AND OVER; AGING; ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEINS E; BLOOD CHEMICAL ANALYSIS; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; FAMILY HEALTH; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENETIC VARIATION; GENOTYPE; HUMANS; INHERITANCE PATTERNS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MODELS, GENETIC; PARENTS; PEDIGREE; PROSPECTIVE STUDIES;

EID: 70349336014     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181b59c2e     Document Type: Article

References (39)

1. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261: 921-923.
2. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 2002;155:487-495.
3. Pedersen WA, Chan SL, Mattson MP. A mechanism for the neuroprotective effect of apolipoprotein E: isoformspecific modification by the lipid peroxidation product 4-hydroxynonenal. J Neurochem 2000;74:1426-1433.
4. Jofre-Monseny L, Minihane AM, Rimbach G. Impact of apoE genotype on oxidative stress, inflammation and disease risk. Mol Nutr Food Res 2008;52:131-145. (Pubitemid 351211806)
5. Taddei K, Clarnette R, Gandy SE, Martins RN. Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease. Neurosci Lett 1997;223:29-32.
6. Folin M, Baiguera S, Conconi MT, et al. Apolipoprotein E as vascular risk factor in neurodegenerative dementia. Int J Mol Med 2004;14:609-613.
7. Slooter AJ, de Knijff P, Hofman A, et al. Serum apolipoprotein E level is not increased in Alzheimer's disease: the Rotterdam study. Neurosci Lett 1998;248:21-24.
8. Scacchi R, Gambina G, Ruggeri M, et al. Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer's disease. Neurosci Lett 1999;259:33-36.
9. Siest G, Bertrand P, Qin B, et al. Apolipoprotein E polymorphism and serum concentration in Alzheimer's diseasein nine European centres: the ApoEurope study. ApoEurope group. Clin Chem Lab Med 2000;38:721-730.
10. Mooijaart SP, van Vliet P, van Heemst D, et al. Plasma levels of apolipoprotein E and cognitive function in old age. Ann NY Acad Sci 2007;1100:148-161. (Pubitemid 47092647)
11. Mooijaart SP, Berbee JF, van Heemst D, et al. ApoE plasma levels and risk of cardiovascular mortality in old age. PLoS Med 2006;3:e176.
12. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
13. Gatz M, Reynolds CA, Fratiglioni L, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 2006;63:168-174.
14. van Duijn CM, Clayton D, Chandra V, et al. Familial aggregation of Alzheimer's disease and related disorders: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol 1991;20(suppl 2): S13-S20.
15. Beekman M, Heijmans BT, Martin NG, et al. Heritabilities of apolipoprotein and lipid levels in three countries. Twin Res 2002;5:87-97.
16. van den Elzen P, Garg S, Leon L, et al. Apolipoproteinmediated pathways of lipid antigen presentation. Nature 2005;437:906-910.
17. Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 2005;4:487-499.
18. van Vliet P, van de Water W, de Craen AJ, Westendorp RG. The influence of age on the association between cholesterol and cognitive function. Exp Gerontol 2009;44: 112-122.
19. Li L, Thompson PA, Kitchens RL. Infection induces a positive acute phase apolipoprotein E response from a negative acute phase gene: role of hepatic LDL receptors. J Lipid Res 2008;49:1782-1793.
20. Klos K, Shimmin L, Ballantyne C, et al. APOE/C1/C4/C2 hepatic control region polymorphism influences plasma apoE and LDL cholesterol levels. Hum Mol Genet 2008; 17:2039-2046.
21. Lambert JC, Brousseau T, Defosse V, et al. Independent association of an APOE gene promoter polymorphism with increased risk of myocardial infarction and decreased APOE plasma concentrations: the ECTIM study. Hum Mol Genet 2000;9:57-61.
22. Scacchi R, Gambina G, Martini MC, et al. Polymorphisms of the apolipoprotein E gene regulatory region and of the LDL receptor gene in late-onset Alzheimer's disease in relation to the plasma lipidic pattern. Dement Geriatr Cogn Disord 2001;12:63-68. (Pubitemid 32149709)
23. Laws SM, Taddei K, Martins G, et al. The -491AA polymorphism in the APOE gene is associated with increased plasma apoE levels in Alzheimer's disease. Neuroreport 1999;10:879-882.
24. Lambert JC, Araria-Goumidi L, Myllykangas L, et al. Contribution of APOE promoter polymorphisms to Alzheimer's disease risk. Neurology 2002;59:59-66.
25. Artiga MJ, Bullido MJ, Frank A, et al. Risk for Alzheimer's disease correlates with transcriptional activity of the APOE gene. Hum Mol Genet 1998;7:1887-1892.
26. Chou CY, Jen WP, Hsieh YH, Shiao MS, Chang GG. Structural and functional variations in human apolipoprotein E3 and E4. J Biol Chem 2006;281:13333-13344.
27. Lund-Katz S, Wehrli S, Zaiou M, Newhouse Y, Weisgraber KH, Phillips MC. Effects of polymorphism on the microenvironment of the LDL receptor-binding region of human apoE. J Lipid Res 2001;42:894-901.
28. Jackson KG, Wolstencroft EJ, Bateman PA, Yaqoob P, Williams CM. Acute effects of meal fatty acids on postprandial NEFA, glucose and apo E response: implications for insulin sensitivity and lipoprotein regulation? Br J Nutr 2005;93:693-700.
29. Georgopoulos A, Applebaum-Bowden D, Margolis S. Improved glycemic control lowers plasma apoprotein E and triglyceride levels following ingestion of a fat load in insulindependent diabetic subjects. Metabolism 1988;37:837-843. (Pubitemid 18226563)
30. Blum CB. Dynamics of apolipoprotein E metabolism in humans. J Lipid Res 1982;23:1308-1316.
31. Moreno JA, Lopez-Miranda J, Marin C, et al. The influence of the apolipoprotein E gene promoter (-219G/T) polymorphism on postprandial lipoprotein metabolism in young normolipemic males. J Lipid Res 2003;44:2059-2064.
32. Pirttila T, Soininen H, Heinonen O, et al. Apolipoprotein E (apoE) levels in brains from Alzheimer disease patients and controls. Brain Res 1996;722:71-77.
33. Beffert U, Cohn JS, Petit-Turcotte C, et al. Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are diseaserelated and apolipoprotein E genotype dependent. Brain Res 1999;843:87-94.
34. Landen M, Hesse C, Fredman P, Regland B, Wallin A, Blennow K. Apolipoprotein E in cerebrospinal fluid from patients with Alzheimer's disease and other forms of dementia is reduced but without any correlation to the apoE4 isoform. Dementia 1996;7:273-278.
35. Song H, Saito K, Seishima M, Noma A, Urakami K, Nakashima K. Cerebrospinal fluid apo E and apo A-I concentrations in early- and late-onset Alzheimer's disease. Neurosci Lett 1997;231:175-178.
36. Lefranc D, Vermersch P, Dallongeville J, Daems-Monpeurt C, Petit H, Delacourte A. Relevance of the quantification of apolipoprotein E in the cerebrospinal fluid in Alzheimer's disease. Neurosci Lett 1996;212: 91-94.
37. Hahne S, Nordstedt C, Ahlin A, Nyback H. Levels of cerebrospinal fluid apolipoprotein E in patients with Alzheimer's disease and healthy controls. Neurosci Lett 1997; 224:99-102.
38. Lindh M, Blomberg M, Jensen M, et al. Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease patients are increased at follow up and show a correlation with levels of tau protein. Neurosci Lett 1997; 229:85-88.
39. Merched A, Blain H, Visvikis S, Herbeth B, Jeandel C, Siest G. Cerebrospinal fluid apolipoprotein E level is increased in late-onset Alzheimer's disease. J Neurol Sci 1997;145:33-39.